Polymerase chain reaction ribotyping of Clostridium difficile isolates in Qatar: a hospital-based study

BMC Infectious Diseases

Sanjay H Doiphode¹  Naser A Al-Ansari¹  Wedad S Hamdi²  Asma A Al-Thani² 

[1] Department of Laboratory Medicine and Pathology, Al-Khor Hospital, Hamad Medical Corporation, Doha, Qatar;Virology Health Sciences Department, College of Arts and Sciences, Qatar University, Doha, Qatar

关键词: Qatar;    Ribotype;    Clostridium difficile;   

Others  :  1125554
DOI  :  10.1186/1471-2334-14-502

 received in 2014-06-05, accepted in 2014-09-10,  发布年份 2014

【 摘 要 】

Background

Clostridium difficile infection (CDI) is not generally reported to public health authorities in the Middle East and its true prevalence remains largely unknown. The aims of this study were to determine the prevalence of CDI and its associated ribotypes among C. difficile isolates in Qatar. Influence of age and correlation with other risk factors e.g. proton pump inhibitor use, antibiotic use, existence of chronic conditions, etc was also investigated for CDI positive patients.

Methods

A total of 1,532 patients with suspected CDI were recruited from two hospitals between 2011 and 2012. C. difficile was identified using glutamate dehydrogenase (GDH) lateral flow assay and toxins A and B Enzyme Immunoassay (EIA). The C. difficile positive samples were then cultured for PCR-ribotyping.

Results

122 of the 1,532 (7.9%) samples from individual patients were identified as C.difficile positive; and 79 of these were viably cultured (~65%). From these, 36 different PCR ribotypes were isolated, of which strains 258 (6 [7.6%]), 01/014/046 (5 [6.3%]), and 011/053/056/107 (4 [5%]) were the most prevalent. The prevalence of PCR-ribotype 027 was 1.3% (n = 1). An age of ≥65 years and treatment with proton pump inhibitors correlated with higher frequency of CDI. Treatment with third generation cephalosporins (50 [41%]) and piperacillin/tazobactam antibiotics (55 [45.1%]) was most frequently associated with CDI.

Conclusion

The most common C. difficile ribotype identified in Qatar was 258, which is different from those found in North America, Europe and Asia. The prevalence of CDI was higher in Qatar than Europe; though comparable to other Middle Eastern countries. These findings underscore the importance of local surveillance to detect and control C. difficile infection.

【 授权许可】

   
2014 Al-Thani et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bartlett JG, Gerding DN: Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S12-S18.
• [2]Choi HK, Kye Kim H, Lee SH, Lee SJ: Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization. J Korean Med Sci 2011, 26(7):859-864.
• [3]Al-Barrak A, Embil J, Dyck B, Olekson K, Nicoll D, Alfa M, Kabani A: An outbreak of toxin A negative, toxin B positive Clostridium difficile-associated diarrhea in a Canadian tertiary-care hospital. Can Commun Dis Rep 1999, 25(7):65-69.
• [4]Kuijper E, Weerdt J, Kato H, Kato N, Dam A, Vorm E, Weel J, Rheenen C, Dankert J: Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain. Eur J Clin Microbiol Infect Dis 2001, 20(8):528-534.
• [5]Drudy D, Harnedy N, Fanning S, Hannan M, Kyne L: Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol 2007, 28(8):932-940.
• [6]Sadeghifard N, Salari MH, Ghassemi MR, Eshraghi S, Amin Harati F: The incidence of nosocomial toxigenic Clostridium difficile associated diarrhea in Tehran tertiary medical centers. Acta Med Iran 2010, 48(5):320-325.
• [7]Collins DA, Hawkey PM, Riley TV: Epidemiology of Clostridium difficile infection in Asia. Antimicrob Resis Inf Cont 2013, 2:21. BioMed Central Full Text
• [8]Abasaeed AE, Vlcek J, Abuelkhair MA, Andrajati R, Elnour AA: A comparative study between prescribed and over-the-counter antibiotics. Saudi Med J 2013, 34(10):1048-1054.
• [9]Zolaly MA, Hanafi MI: Factors affecting antibiotics’ prescription in general pediatric clinics. J Taibah Univ Med Sci 2011, 6(1):33-41.
• [10]Abasaeed A, Vlcek J, Abuelkhair M, Kubena A: Self-medication with antibiotics by the community of Abu Dhabi Emirate, United Arab Emirates. J Infect Dev Ctries 2009, 3(7):491-497.
• [11]Suleiman IS, Rubian SS: Antibiotics use with and without a prescription in healthcare students. Am J Pharmac Sci 2013, 1(5):96-99.
• [12]Dar-Odeh NS, Abu-Hammad OA, Khraisat AS, El Maaytah MA, Shehabi A: An analysis of therapeutic, adult antibiotic prescriptions issued by dental practitioners in Jordan. Chemotherapy 2008, 54(1):17-22.
• [13]Hastings M: Anaerobe Reference Unit Operating Procedure Manual ASOP 39: PCR Ribotyping of Clostridium difficile. 2006. [NPHS Microbiology Cardiff, issue 1, issue date 13/11/06]
• [14]Jalali M, Khorvash K, Warriner K, Scott J: Clostridium difficile infection in an Iranian hospital. BMC Res Notes 2012, 5:159. BioMed Central Full Text
• [15]Sadeghifard N, Salari MH, Ranjbar R, Ghafouryan S, Raftari M, Abdulamir AS, Fatimah AB, Kazemi B: The clinical and environmental spread and diversity of toxigenic Clostridium difficile diarrheic in the region of the Middle East. Rev Infection 2010, 1:180-187.
• [16]Jamal W, Rotimi VO, Brazier J, Duerden BI: Analysis of prevalence, risk factors and molecular epidemiology of Clostridium difficile infection in Kuwait over a 3-year period. Anaerobe 2010, 16(6):560-565.
• [17]Nasereddin LM, Bakri FG, Shehabi AA: Clostridium difficile infections among Jordanian adult hospitalized patients. Am J Infection Control 2009, 37(10):864-866.
• [18]Rotimi VO, Mokaddas EM, Jamal WY, Verghese TL, el-Din K, Junaid TA: Hospital-acquired Clostridium difficile infection amongst ICU and burn patients in Kuwait. Med Princ Pract 2002, 11(1):23-28.
• [19]European Centre for Disease Prevention and Control: Point prevalence survey. http://www.ecdc.europa.eu/en/healthtopics/Healthcare-associated_infections/point-prevalence-survey/Pages/Point-prevalence-survey.aspx webcite Last accessed May 2014
• [20]Jalali M, Khorvash F, Warriner K, Weese JS: Clostridium difficile infection in an Iranian hospital. BMC Res Notes 2012, 5:159. BioMed Central Full Text
• [21]Sawabe E, Kato H, Osawa K, Chida T, Tojo N, Arakawa Y, Okamura NL: Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period. Eur J Clin Microbiol Infect Dis 2007, 26(10):695-703.
• [22]Kim H, Lee Y, Moon HW, Lim CS, Lee K, Chong Y: Emergence of Clostridium difficile ribotype 027 in Korea. Korean J Lab Med 2011, 31(3):191-196.
• [23]Cheng VC, Yam WC, Lam OT, Tsang JL, Tse EY, Siu GK, Chan JF, Tse H, To KK, Tai JW, Ho PL, Yuen KY: Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong. Eur J Clin Microbiol Infect Dis 2011, 30(11):1371-1381.
• [24]Lim PL, Ling ML, Lee HY, Koh TH, Tan AL, Kuijper EJ, Goh SS, Low BS, Ang LP, Harmanus C, Lin RT, Krishnan P, James L, Lee CE: Isolation of the first three cases of Clostridium difficile polymerase chain reaction ribotype 027 in Singapore. Singapore Med J 2011, 52(5):361-364.
• [25]Kato H, Ito Y, van den Berg RJ, Kuijper EJ, Arakawa Y: First isolation of Clostridium difficile 027 in Japan. Euro Surveill 2007, 12(1):E070111.3.
• [26]Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ: ECDIS Study Group. Lancet 2011, 377(9759):63-73.
• [27]Kuijper EJ, Coignard B, Brazier JS, Suetens C, Drudy D, Wiuff C, Pituch H, Reichert P, Schneider F, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Barbut F, Delmée M, Wilcox M, Pearson A, Patel BC, Brown DJ, Frei R, Akerlund T, Poxton IR, Tüll P: Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill 2007, 12(6):E1-E2.
• [28]de Lalla F, Privitera G, Ortisi G, Rizzardini G, Santoro D, Pagano A, Rinaldi E, Scarpellini P: Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital. J Antimicrob Chemother 1989, 23(4):623-631.
• [29]Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA: Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S19-S31.
• [30]Mendez MN, Gibbs L, Jacobs RA, McCulloch CE, Winston L, Guglielmo BJ: Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections. Pharmacotherapy 2006, 26(1):61-67.
• [31]Garneau JR, Valiquette L, Fortier LC: Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC Infect Dis 2014, 14:29. BioMed Central Full Text
• [32]Kuijper EJ, Coignard B, Tüll P: Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006, 12(Suppl. 6):2-18.
• [33]Henrich TJ, Krakower D, Bitton A, Yokoe DS: Clinical risk-factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009, 15:415-422.
• [34]Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, Alam HB, DeMoya MA, Velmahos GC: Fulminant Clostridium difficile colitis. patterns of care and predictors of mortality. Arch Surg 2009, 144:433-439.
• [35]U.S. Food and Drug Administration: FDA Drug Safety Communication: clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). http://www.fda.gov/drugs/drugsafety/ucm290510.htm webcite Last accessed May 2014